Performance monitoring in lung cancer patients pre- and post-chemotherapy using fine-grained electrophysiological measures

Simó, Marta; Gurtubay-Antolin, Ane; Vaquero, Lucía; Bruna, Jordi; Rodrı́guez-Fornells, Antoni

doi:10.1016/j.nicl.2017.12.032

Cited by 14 publications

(7 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The analysis of the paired groups showed that decreased volumes were found in more extensive regions, including the frontal, parietal, temporal, occipital, limbic, insular, and partial cerebellar regions. This result is consistent with that of previous studies ( 18 , 35 – 37 ) and is probably caused by the shorter duration after chemotherapy in the patients of the paired groups, in which the brain regions were temporarily injured and in a recovering state partly ( 21 , 38 ).…”

Section: Discussionsupporting

confidence: 93%

“…Additionally, patients with chemotherapy have a greater reduction in temporal lobe volume than those without, and this was associated with a decrease in oral reading recognition scores ( 14 , 19 , 20 ). Hippocampal deformation or volume reduction is another abnormal change in patients receiving chemotherapy, and these changes are related to memory, long education years, poor self-reported cognitive function evaluation, and even a significant increase in inflammatory immune specific interleukin-6 and tumor necrosis factor-α ( 21 – 24 ). A recent study using gray matter density (GMD) as a parameter indicated that GMD decreased in the left inferior frontal gyrus, right middle frontal gyrus, right fusiform area, and both cerebellums in patients after chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Brain morphological alterations and their correlation to tumor differentiation and duration in patients with lung cancer after platinum chemotherapy

Chen

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveChemotherapy-related brain impairments and changes can occur in patients with lung cancer after platinum chemotherapy and have a substantial impact on survivors’ quality of life. Therefore, it is necessary to understand the brain neuropathological alterations and response mechanisms to provide a theoretical basis for rehabilitation strategies. This study aimed to investigate the related brain morphological changes and clarified their correlation with clinical and pathological indicators in patients with lung cancer after platinum chemotherapy.MethodsOverall, 28 patients with chemotherapy, 56 patients without chemotherapy, and 41 healthy controls were categorized in three groups, matched for age, sex, and years of education, and included in the cross-sectional comparison of brain volume and cortical thickness. 14 matched patients before and after chemotherapy were subjected to paired comparison for longitudinal observation of brain morphological changes. Three-dimensional T1-weighted images were acquired from all participants, and quantitative parameters were calculated using the formula of the change from baseline. Correlation analysis was performed to evaluate the relationship between abnormal morphological indices and clinical information of patients.ResultsBrain regions with volume differences among the three groups were mainly distributed in frontal lobe and limbic cortex. Additionally, significant differences in cerebrospinal fluid were observed in most ventricles, and the main brain regions with cortical thickness differences were the gyrus rectus and medial frontal cortex of the frontal lobe, transverse temporal gyrus of the temporal lobe, insular cortex, anterior insula, and posterior insula of the insular cortex. According to the paired comparison, decreased brain volumes in the patients after chemotherapy appeared in some regions of the frontal, parietal, temporal, and occipital lobes; limbic cortex; insular cortex; and lobules VI-X and decreased cortical thickness in the patients after chemotherapy was found in the frontal, temporal, limbic, and insular cortexes. In the correlation analysis, only the differentiation degree of the tumor and duration after chemotherapy were significantly correlated with imaging indices in the abnormal brain regions.ConclusionsOur findings illustrate the platinum-related brain reactivity morphological alterations which provide more insights into the neuropathological mechanisms of patients with lung cancer after platinum chemotherapy and empirical support for the details of brain injury related to cancer and chemotherapy.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Brain morphological alterations and their correlation to tumor differentiation and duration in patients with lung cancer after platinum chemotherapy

Chen

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…This problem must be tackled to bring patients back to their premorbid quality of life. Chemobrain is most pronounced in population of patients with breast cancer with a frequency reaching 80% [13], but it also includes lung cancer (30% of patients) [14], Central nervous system (CNS) malignancies [6], testicular cancer [15], and hematologic malignancies [16–18], and these deficits appear following treatment with various chemotherapeutic agents that have different mechanisms of action [6]. Pre-treatment cognitive screening did not reveal profound cognitive impairment [19], although some studies point to brain structure abnormalities also in cancer patients not subjected to chemotherapy [20–22].…”

Section: Chemobrainmentioning

confidence: 99%

Chemobrain as a Product of Growing Success in Chemotherapy - Focus On Glia As Both A Victim And A Cure

Walczak¹,

Janowski²

2019

Neuropsychiatry

View full text Add to dashboard Cite

Chemotherapy-induced cognitive impairment or chemobrain is a frequent consequence of cancer treatment with many psychiatric features. Ironically, the increasing efficacy of chemotherapy leaves growing number of patients alive with chemobrain. Therefore, there is an urgent need for strategies capable of returning cancer survivors back to their pre-morbid quality of life. Molecular mechanisms of chemobrain are largely unknown. Over the last decade there was a lot of emphasis in preclinical research on inflammatory consequences of chemotherapy and oxidative stress but so far none of these approaches were translated into clinical scenario. The co-administration of chemotherapy with protective agents was evaluated preclinically but it should be introduced with caution as potential interference was not yet studied and that could blunt therapeutic efficacy. Stem cell-based regenerative medicine approach has so far been exploited very sparsely in the context of chemobrain and the focus was on indirect mechanisms or neuronal replacement in the hippocampus. However, there is evidence for widespread white matter abnormalities in patients with chemobrain. This is quite logical considering life-long proliferation and turnover of glial cells, which makes them vulnerable to chemotherapeutic agents. Feasibility of glia replacement has been established in mice with global dysmyelination where profound therapeutic effect has been observed but only in case of global cell engraftment (across the entire brain). While global glia replacement has been achieved in mice translation to clinical setting might be challenging due to much larger brain size. Therefore, a lot of attention should be directed towards the route of administration to accomplish widespread cell delivery. Techniques facilitating that broad cell distribution including intra-arterial and intrathecal methods should be considered as very compelling options. Summarizing, chemobrain is a rapidly growing medical problem and global glia replacement should be considered as worthwhile therapeutic strategy.

show abstract

“…Test scores may not fully capture subtle neurophysiological changes that occur after cancer treatment [ 14 ]. Pairing EF tasks, such as the letter n-back (capturing working memory; [ 15 ]) or the Go/No Go (capturing response inhibition; [ 16 ]), with neuroimaging techniques can be used to explore neural activity during EF task performance [ 17 , 18 ]. Functional magnetic resonance imaging (fMRI) is one neuroimaging technique that can help detect differences in neural activity underlying EF, even in the absence of performance or detectable structural changes [ 19 , 20 ].…”

Section: Introductionmentioning

confidence: 99%

A proof-of-concept sub-study exploring feasibility and preliminary evidence for the role of physical activity on neural activity during executive functioning tasks among young adults after cancer treatment

et al. 2021

View full text Add to dashboard Cite

Background Executive functioning (EF) deficits are troubling for adolescents and young adults (AYAs) after cancer treatment. Physical activity (PA) may enhance neural activity underlying EF among older adults affected by cancer. Establishing whether PA enhances neural activity among AYAs is warranted. As part of a two-arm, mixed-methods pilot randomized controlled trial (RCT), this proof-of-concept sub-study sought to answer the following questions: (1) is it feasible to use neuroimaging with EF tasks to assess neural activity changes following a 12-week PA intervention? And (2) is there preliminary evidence that a 12-week PA intervention enhances neural activity among AYAs after cancer treatment? Methods AYAs in the pilot RCT were approached for enrollment into this sub-study. Those who were eligible and enrolled, completed functional magnetic resonance imaging (fMRI) with EF tasks (letter n-back, Go/No Go) pre- and post-PA intervention. Sub-study enrollment, adherence to scheduled fMRI scans, outliers, missing data, and EF task performance data were collected. Data were analyzed with descriptive statistics, blood oxygen level dependent (BOLD) analyses, and paired sample t-tests. Results Nine eligible participants enrolled into this sub-study; six attended scheduled fMRI scans. One outlier was identified and was subsequently removed from the analytical sample. Participants showed no differences in EF task performance from pre- to post-PA intervention. Increases in neural activity in brain regions responsible for motor control, information encoding and processing, and decision-making were observed post-PA intervention (p < 0.05; n = 5). Conclusions Findings show that fMRI scans during EF tasks detected neural activity changes (as assessed by the BOLD signal) from pre- to post-PA intervention. Results thus suggest future trials confirming that PA enhances neural activity underlying EF are needed, though feasibility issues require careful consideration to ensure trial success. Trial registration clinicaltrials.gov, NCT03016728. Registered January 11, 2017, clinicaltrials.gov/ct2/show/NCT03016728.

show abstract

Performance monitoring in lung cancer patients pre- and post-chemotherapy using fine-grained electrophysiological measures

Cited by 14 publications

References 78 publications

Brain morphological alterations and their correlation to tumor differentiation and duration in patients with lung cancer after platinum chemotherapy

Brain morphological alterations and their correlation to tumor differentiation and duration in patients with lung cancer after platinum chemotherapy

Chemobrain as a Product of Growing Success in Chemotherapy - Focus On Glia As Both A Victim And A Cure

A proof-of-concept sub-study exploring feasibility and preliminary evidence for the role of physical activity on neural activity during executive functioning tasks among young adults after cancer treatment

Contact Info

Product

Resources

About